Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
ATOS's Cash-to-Debt is ranked higher than
86% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. ATOS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ATOS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: N/A Max: No Debt
Current: No Debt
Interest Coverage No Debt
ATOS's Interest Coverage is ranked higher than
87% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. ATOS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ATOS' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 9999.5 Max: No Debt
Current: No Debt
N/A
No Debt
Piotroski F-Score: 4
Altman Z-Score: -12.42
Beneish M-Score: -5.31
WACC vs ROIC
12.74%
-1258.82%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -406600.00
ATOS's Operating Margin % is ranked lower than
100% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. ATOS: -406600.00 )
Ranked among companies with meaningful Operating Margin % only.
ATOS' s Operating Margin % Range Over the Past 10 Years
Min: -637950  Med: -30427.5 Max: -1051.66
Current: -406600
-637950
-1051.66
Net Margin % -318450.00
ATOS's Net Margin % is ranked lower than
100% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. ATOS: -318450.00 )
Ranked among companies with meaningful Net Margin % only.
ATOS' s Net Margin % Range Over the Past 10 Years
Min: -788000  Med: -36645 Max: -1053.94
Current: -318450
-788000
-1053.94
ROE % -172.73
ATOS's ROE % is ranked lower than
92% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. ATOS: -172.73 )
Ranked among companies with meaningful ROE % only.
ATOS' s ROE % Range Over the Past 10 Years
Min: -972.32  Med: -150.83 Max: -136.71
Current: -172.73
-972.32
-136.71
ROA % -127.13
ATOS's ROA % is ranked lower than
90% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. ATOS: -127.13 )
Ranked among companies with meaningful ROA % only.
ATOS' s ROA % Range Over the Past 10 Years
Min: -7246.67  Med: -149.18 Max: -102.65
Current: -127.13
-7246.67
-102.65
ROC (Joel Greenblatt) % -7108.39
ATOS's ROC (Joel Greenblatt) % is ranked lower than
96% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. ATOS: -7108.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ATOS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8258.25  Med: -6677.4 Max: -1128.17
Current: -7108.39
-8258.25
-1128.17
3-Year Revenue Growth Rate -88.00
ATOS's 3-Year Revenue Growth Rate is ranked lower than
100% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. ATOS: -88.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ATOS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -88 Max: 102.7
Current: -88
0
102.7
3-Year EBITDA Growth Rate 3.50
ATOS's 3-Year EBITDA Growth Rate is ranked lower than
91% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. ATOS: 3.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ATOS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 3.5  Med: 9.2 Max: 54.8
Current: 3.5
3.5
54.8
3-Year EPS without NRI Growth Rate 3.00
ATOS's 3-Year EPS without NRI Growth Rate is ranked lower than
89% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. ATOS: 3.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ATOS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 3  Med: 10.3 Max: 57.3
Current: 3
3
57.3
GuruFocus has detected 1 Warning Sign with Atossa Genetics Inc $ATOS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ATOS's 10-Y Financials

Financials (Next Earnings Date: 2017-08-15 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ATOS Guru Trades in Q1 2016

Jim Simons 272,562 sh (+148.32%)
» More
Q2 2016

ATOS Guru Trades in Q2 2016

Jim Simons 352,262 sh (+29.24%)
» More
Q3 2016

ATOS Guru Trades in Q3 2016

Jim Simons 41,311 sh (+75.91%)
» More
Q4 2016

ATOS Guru Trades in Q4 2016

Jim Simons 90,811 sh (+119.82%)
» More
» Details

Insider Trades

Latest Guru Trades with ATOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:OTCPK:ABMC, OTCPK:BMKDF, OTCPK:IMEXF, OTCPK:ETAH, OTCPK:OXIS, NAS:ROSG, OTCPK:MCUIF, OTCPK:MTST, OTCPK:BTHCF, OTCPK:GBSND, OTCPK:DIGP, OTCPK:LEDIF, OTCPK:JFIL, OTCPK:BZYR, OTCPK:INOL, OTCPK:MDIT, NAS:BASI, OTCPK:TBIO, OTCPK:SQIDF, NAS:TEAR » details
Traded in other countries:YAG1.Germany,
Headquarter Location:USA
Atossa Genetics Inc is a clinical-stage pharmaceutical company engaged in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions.

Atossa Genetics Inc was incorporated in Delaware on April 2009. The Company is a healthcare company, engaged in the improvement of breast health through the development of a suite of laboratory developed tests (LDTs), FDA cleared medical devices and therapeutics. Its laboratory tests are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. (the NRLBH), and are intended to address each of the four stages of the breast health care path: the cytological analysis of nipple aspirate fluid (NAF); the cytological analysis of ductal lavage fluid collected from each individual breast duct with its proprietary microcatheters; the profiling of newly diagnosed breast cancers through the determination of gene expression profiles in breast cancer biopsy tissue; and the monitoring of breast cancer survivors for pre-clinical recurrence through a blood test for circulating tumor cells. The Company's medical devices under development include the ForeCYTE Breast Aspirator (510(k) pending, not for sale in the United States) intended for the collection of NAF for cytological testing at a laboratory, intra ductal microcatheters for the collection of ductal lavage fluid and for the potential administration of a targeted therapeutic, and various tools for potential use by breast surgeons. It owns 137 issued patents (45 in the United States and at least 92 in foreign countries), and 11 pending patent applications (9 in the United States and 2 pending International Patent Cooperation Treaty (PCT) application) directed to its products, services, and technologies. The Federal Food, Drug, and Cosmetic Act, or FDCA, and the FDA's implementing regulations, govern registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, and post-market surveillance. Medical devices and the manufacturers are also subject to inspection by the FDA. The FDCA, supplemented by other federal and state laws, also provides civil and criminal penalties for violations of its provisions.

Top Ranked Articles about Atossa Genetics Inc

Atossa Genetics Initiates Additional Drug Development Program

Oral Endoxifen for Patients Refractory to Tamoxifen

SEATTLE, WA--(Marketwired - Jun 7, 2016) -  Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it has initiated a new drug development program with oral endoxifen. Endoxifen is an active metabolite of tamoxifen, an FDA approved drug for breast cancer patients to prevent recurrence as well as new breast cancer. Dr. Steve Quay, President and CEO, commented, "We have made substantial progress with this drug candidate: we have filed patent applications; contracted for the initial drug supply; and we have identified its initial indication -- breast cancer patients who are refractory to tamoxifen thereby getting little or no benefit from the drug. It is estimated that over one million people take tamoxifen annually in the United States and that up to 50% of those patients are refractory for any number of reasons, including low levels of a liver enzyme." Atossa has received valuable input from the Medicines and Healthcare Products Regulatory Agency, or the MHRA, which is the United Kingdom health regulatory authority. Written guidance from the FDA is expected this week. Atossa will pursue strategic initiatives that include completion of the product development to support an IND filing to the FDA, which is anticipated to occur later this year. About Atossa Genetics Atossa Genetics Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com. Forward-Looking Statements Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others, such as patent rights, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K, 10-Q and 8-K, each as amended and supplemented from time to time.


Contact:



Atossa Genetics Inc.

Kyle Guse

CFO and General Counsel

(O) 800-351-3902

[email protected]



Investor Relations:



CorProminence LLC

Scott Gordon

President

(O) 516-222-2560

[email protected]





Read more...
Atossa Genetics Announces $10 Million At-the-Market Common Stock Purchase Agreement With Aspire Capital Fund, LLC

SEATTLE, WA--(Marketwired - May 27, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that it has entered into a $10 million stock purchase agreement with Aspire Capital Fund, LLC. Under terms of the agreement, after the SEC declares the registration statement related to the transaction effective, Aspire has committed to purchase up to $10 million of Atossa's common stock over 30 months, based on prevailing market prices over a period preceding each sale. "Aspire Capital has been an important financial partner over the past three years and we look forward to continuing our work together to execute on our business objectives," stated Kyle Guse, Chief Financial Officer of Atossa Genetics. "This financial arrangement will provide us with the financial resources and flexibility so that we can raise equity based on favorable market conditions and our evolving working capital needs." "We are very pleased to continue our financial relationship with Atossa," said Steve Martin, Principal of Aspire Capital. "We are very excited about Atossa's Phase II clinical program and are happy to be part of Atossa's progress." Key aspects of the agreement with Aspire Capital include:

Atossa will control the timing and amount of any sales of common stock to Aspire Capital and will know the sales price before directing Aspire Capital to purchase shares;
Aspire Capital has no right to require any sales by Atossa, but is obligated to make purchases as Atossa directs, in accordance with the terms of the purchase agreement;
Aspire Capital has agreed to a long-only position;
There are no limitations on use of proceeds, financial covenants, restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the purchase agreement;
The purchase agreement may be terminated by Atossa at any time, at its discretion, without any additional cost or penalty; and
Atossa has issued shares of its common stock to Aspire Capital as a commitment fee in connection with entering into the purchase agreement.
Atossa will use the net proceeds from the sales of common stock for general corporate purposes and working capital requirements.
Atossa also entered into a registration rights agreement with Aspire Capital in connection with its entry into the purchase agreement that requires the Company to file a registration statement regarding the shares sold to Aspire Capital. A more complete and detailed description of the agreement is set forth in the Company's Periodic Report on Form 8-K filed today with the U.S. Securities and Exchange Commission.

About Aspire Capital Fund, LLC Aspire Capital is an institutional investor based in Chicago, Illinois, with a fundamental investment approach. Aspire Capital invests in a wide range of companies and industries emphasizing life sciences, energy and technology. About Atossa Genetics Atossa Genetics, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com. Forward-Looking Statements Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others, such as patent rights, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.


Atossa Genetics Company Contact:


Atossa Genetics Inc.

Kyle Guse

CFO and General Counsel

(O) 800-351-3902

[email protected]


Investor Relations Contact:

Scott Gordon

CorProminence LLC

(O) 516-222-2560

[email protected]





Read more...
Atossa Genetics Announces First Quarter 2016 Financial Results and Provides Company Update

Conference Call to Be Held Today at 4:30 pm Eastern Time

SEATTLE, WA--(Marketwired - May 5, 2016) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced First Quarter ended March 31, 2016 financial results and provided an update on recent company developments. Steve Quay, President and CEO, commented, "We were especially pleased to announce in early March, 2016 the opening for enrollment of our '007' trial, a Phase 2 clinical trial of intraductal fulvestrant administration in women with ductal carcinoma in situ (DCIS) or invasive breast cancer slated for mastectomy or lumpectomy. This study will assess the safety and tolerability of fulvestrant when delivered directly into breast milk ducts of these patients. We look forward to reviewing study data in the second half of the year and are optimistic about its outcomes. The primary endpoint of the clinical trial is to assess the safety and tolerability of intraductal administration of fulvestrant in women with DCIS or Stage 1 or 2 invasive ductal carcinoma prior to mastectomy or lumpectomy. The secondary objective of the study is to determine if there are changes in the expression of Ki67 as well as estrogen and progesterone receptors between a pre-fulvestrant biopsy and post-fulvestrant surgical specimen." Dr. Quay continued, "We are continuing in our strident efforts in identifying one or more additional drug candidates to enhance our business and drive shareholder value." Recent Corporate Developments  Atossa's important recent developments include the following:

In March 2016, Opened Phase 2 Clinical Trial of Intraductal Fulvestrant Administration in Women with DCIS or Breast Cancer in the United States, which is Called the '007 Trial



In December 2015, Completed Sale of Wholly-Owned Subsidiary, The National Reference Laboratory for Breast Health, Inc. (the "NRLBH")



Raised Approximately $2.2 Million in Working Capital through the Sale of Common Stock to Aspire Capital in the First Quarter of 2016





Q1 2016 Financial Results As a result of the sale of the NRLBH in December 2015, we generated no revenue or cost of revenue for the three months ended March 2016. Revenue and cost of service from NRLBH activities are presented as discontinued operations for the three months ended 2015. The NLRBH had total net revenue of $1,871,137 and cost of revenue of $1,206,311, for the three months ended March 31, 2015, consisting of mainly pharmacogenomics testing. Total operating expenses were $2,327,540 for the three months ended March 31, 2016, consisting of general and administrative (G&A) expenses of $2,177,569 and R&D expenses of $149,971. As a result of the sale of NRLBH, operating expenses related to the NRLBH are presented separately as discontinued operations for the three months ended March 31, 2015. Operating expenses from continuing operations for three months ended March 31, 2016 decreased $945,132, or 29%, from $3,272,672 for the three months ended March 31, 2015, which consisted of G&A expenses of $2,361,026, R&D expenses of $565,801, and selling expenses of $345,845. The decrease in operating expenses is mainly attributed to the 2015 launch of new devices and services which are not being pursued in 2016 and investing more in new R&D programs in the first quarter of 2015 compared to 2016. The Company recorded a net loss of $2,327,540, for the three months ended March 31, 2016. The loss from discontinued operations for the three months ended March 31, 2015 was $61,204. Conference Call Information Management will host a conference call today, May 5, 2016, at 4:30 pm Eastern Time to review the financial results and recent corporate developments. To listen to the call by phone, interested parties within the U.S. should call 1-866-652-5200 and International callers should call 1-412-317-6060. All callers should ask for the Atossa Genetics conference call. The conference call will also be available through a live webcast at www.atossagenetics.com. Details for the webcast may be found on the Company's IR events page at http://ir.atossagenetics.com/ir-calendar. A replay of the call will be available approximately one hour after the end of the call through June 5, 2016. The replay can be accessed via Atossa's website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international) or Canada Toll Free at 855-669-9658. The replay conference ID number is 10085791. About Atossa Genetics Atossa Genetics, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com. Forward-Looking Statements Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others, such as patent rights, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.


 
 


ATOSSA GENETICS INC.
 


CONDENSED CONSOLIDATED BALANCE SHEETS
 


 
 


 
 
March 31,
 
 
December 31,
 


 
 
2016
 
 
2015
 


 
 
(Unaudited)
 
 
 
 


Assets
 
 
 
 
 
 
 
 


Current assets
 
 
 
 
 
 
 
 


 
Cash and cash equivalents
 
$
2,882,657
 
  $
3,715,895
 


 
Restricted cash
 
 
275,000
 
 
 
275,000
 


 
Prepaid expense
 
 
227,936
 
 
 
193,293
 


 
Other current assets
 
 
-
 
 
 
110,663
 


 
 
Total current assets
 
 
3,385,593
 
 
 
4,294,851
 


 
 
 
 
 
 
 
 
 


 
Furniture and equipment, net
 
 
145,970
 
 
 
171,568
 


 
Intangible assets, net
 
 
1,492,121
 
 
 
1,700,565
 


 
Other assets
 
 
76,337
 
 
 
76,337
 


 
 
Total assets
 
$
5,100,021
 
 
$
6,243,321
 


 
 
 
 
 
 
 
 
 


Liabilities and Stockholders' Equity
 
 
 
 
 
 
 
 


 
 
 
 
 
 
 
   


Current liabilities
 
 
 
 
 
 
 
 


 
Accounts payable
 
$
429,052
 
 
$
814,448
 


 
Accrued expenses
 
 
169,001
 
 
 
463,676
 


 
Payroll liabilities
 
 
724,934
 
 
 
1,159,335
 


 
Other current liabilities
 
 
3,848
 
 
 
64,128
 


 
 
Total current liabilities
 
 
1,326,835
 
 
 
2,501,587
 


 
 
 
 
 
 
 
 
 


Stockholders' equity
 
 
 
 
 
 
 
 


 
Preferred stock - $.001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding
 
 
-
 
 
 
-
 


 
Common stock - $.001 par value; 75,000,000 shares authorized, 38,823,464 and 32,657,257 shares issued and outstanding
 
 
38,823
 
 
 
32,657
 


 
Additional paid-in capital
 
 
56,996,766
 
 
 
54,643,940
 


 
Accumulated deficit
 
 
(53,262,403
)
 
 
(50,934,863
)

 
 
Total stockholders' equity
 
 
3,773,186
 
 
 
3,741,734
 


 
 
 
 
 
 
 
 
 


 
Total liabilities and stockholders' equity
 
$
5,100,021
 
 
$
6,243,321
 


 
 
 
 
 
 
 
 
 






 
 


ATOSSA GENETICS INC.
 


CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
 


(UNAUDITED)
 


 
 


 
 
For the Three Months Ended

March 31,
 


 
 
2016
 
 
2015
 


Net revenue
 
 
-
 
 
 
-
 


Cost of revenue
 
 
-
 
 
 
-
 


 
Gross profit
 
 
-
 
 
 
-
 


Selling expenses
 
 
-
 
 
 
345,845
 


Research and development expenses
 
 
149,971
 
 
 
565,801
 


General and administrative expenses
 
 
2,177,569  
 
 
2,361,026
 


 
Total operating expenses
 
 
2,327,540
 
 
 
3,272,672
 


Operating loss
 
 
(2,327,540
)
 
 
(3,272,672
)


Other expenses
 
 
-
 
 
 
(1,415
)


Loss before income taxes
 
 
(2,327,540
)
 
 
(3,274,087
)


Income taxes
 
 
-
 
 
 
-
 


Loss from continuing operations
 
$
(2,327,540
)
 
$
(3,274,087
)


Loss from discontinued operations
 
 
-
 
 
 
(61,204
)


Net loss
 
$
(2,327,540
)
 
$
(3,335,291
)


Loss per common share from continuing operations - basic and diluted
 
$
(0.07
)
 
$
(0.13
)


Loss per common share from discontinued operations- basic and diluted
 
 
-
 
 
 
-
 


Loss per common share - basic and diluted
 
$
(0.07
)
 
$
(0.13 )


Weighted average shares outstanding, basic and diluted
 
 
31,511,623
 
 
 
24,916,867
 


 
 
 
 
 
 
 
 
 





Atossa Genetics Company Contact:



Atossa Genetics Inc.

Kyle Guse

CFO and General Counsel

(O) 800-351-3902

[email protected]



Investor Relations Contact



Scott Gordon

CorProminence LLC

377 Oak Street

Concourse 2

Garden City, NY 11530

Office: 516.222.2560

[email protected]





Read more...
Atossa Genetics to Host First Quarter 2016 Financial Results and Company Update Conference Call on Thursday, May 5, 2016

SEATTLE, WA--(Marketwired - May 3, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that it will host a conference call on Thursday May 5, 2016 at 4:30 pm eastern time to review First Quarter ended March 31, 2016 financial results and provide a company update. Following management's formal remarks, there will be a question and answer session. To listen to the call by phone, interested parties within the U.S. should call 1-866-652-5200 and International callers should call 1-412-317-6060. All callers should ask for the Atossa Genetics conference call. The conference call will also be available through a live webcast at www.atossagenetics.com. Details for the webcast may be found on the Company's IR events page at http://ir.atossagenetics.com/ir-calendar. A replay of the call will be available approximately one hour after the end of the call through June 5, 2016. The replay can be accessed via Atossa's website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international) or Canada Toll Free at 855-669-9658. The replay conference ID number is 10085791. About Atossa Genetics

Atossa Genetics, Inc. is developing novel and locally-administered pharmaceuticals to address breast conditions, including cancer. For more information, please visit www.atossagenetics.com. Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.


Atossa Genetics Company Contact:


Atossa Genetics, Inc.

Kyle Guse

CFO and General Counsel

(O) 800-351-3902

[email protected]


Investor Relations Contact

Scott Gordon

CorProminence LLC

377 Oak Street

Concourse 2

Garden City, NY 11530

Office: 516.222.2560

[email protected]





Read more...

Ratios

vs
industry
vs
history
PB Ratio 0.72
ATOS's PB Ratio is ranked higher than
94% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. ATOS: 0.72 )
Ranked among companies with meaningful PB Ratio only.
ATOS' s PB Ratio Range Over the Past 10 Years
Min: 0.41  Med: 3.03 Max: 22.34
Current: 0.72
0.41
22.34
EV-to-EBIT 0.10
ATOS's EV-to-EBIT is ranked higher than
99% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. ATOS: 0.10 )
Ranked among companies with meaningful EV-to-EBIT only.
ATOS' s EV-to-EBIT Range Over the Past 10 Years
Min: -24.7  Med: -1.8 Max: 0.3
Current: 0.1
-24.7
0.3
EV-to-EBITDA 0.11
ATOS's EV-to-EBITDA is ranked higher than
99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. ATOS: 0.11 )
Ranked among companies with meaningful EV-to-EBITDA only.
ATOS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.7  Med: -1.9 Max: 0.3
Current: 0.11
-25.7
0.3
Current Ratio 5.28
ATOS's Current Ratio is ranked higher than
59% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. ATOS: 5.28 )
Ranked among companies with meaningful Current Ratio only.
ATOS' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.72 Max: 16.36
Current: 5.28
0.01
16.36
Quick Ratio 5.28
ATOS's Quick Ratio is ranked higher than
65% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. ATOS: 5.28 )
Ranked among companies with meaningful Quick Ratio only.
ATOS' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.7 Max: 16.36
Current: 5.28
0.01
16.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -36.30
ATOS's 3-Year Average Share Buyback Ratio is ranked lower than
83% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. ATOS: -36.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ATOS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.8  Med: -39.2 Max: -36.3
Current: -36.3
-45.8
-36.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 0.63
ATOS's Price-to-Net-Cash is ranked higher than
96% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.15 vs. ATOS: 0.63 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ATOS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.63  Med: 7.36 Max: 650
Current: 0.63
0.63
650
Price-to-Net-Current-Asset-Value 0.60
ATOS's Price-to-Net-Current-Asset-Value is ranked higher than
95% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. ATOS: 0.60 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ATOS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.6  Med: 5.84 Max: 150
Current: 0.6
0.6
150
Price-to-Tangible-Book 0.91
ATOS's Price-to-Tangible-Book is ranked higher than
93% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. ATOS: 0.91 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ATOS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.91  Med: 5.28 Max: 93.9
Current: 0.91
0.91
93.9
Price-to-Median-PS-Value 0.81
ATOS's Price-to-Median-PS-Value is ranked lower than
99.99% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. ATOS: 0.81 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ATOS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 0.79 Max: 7.91
Current: 0.81
0.07
7.91
Earnings Yield (Greenblatt) % 1000.00
ATOS's Earnings Yield (Greenblatt) % is ranked higher than
99% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. ATOS: 1000.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ATOS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 310.4  Med: 1725.95 Max: 6509.3
Current: 1000
310.4
6509.3

More Statistics

Revenue (TTM) (Mil) $0.00
EPS (TTM) $ -2.30
Beta1.74
Short Percentage of Float4.26%
52-Week Range $0.57 - 6.15
Shares Outstanding (Mil)6.01

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) -3.57 -2.04
EPS without NRI ($) -3.57 -2.04
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ATOS

Headlines

Articles On GuruFocus.com
Atossa Genetics Initiates Additional Drug Development Program Jun 07 2016 
Atossa Genetics Announces $10 Million At-the-Market Common Stock Purchase Agreement With Aspire Capi May 27 2016 
Atossa Genetics Announces First Quarter 2016 Financial Results and Provides Company Update May 05 2016 
Atossa Genetics to Host First Quarter 2016 Financial Results and Company Update Conference Call on T May 03 2016 
Atossa Genetics to Host 2015 Financial Results and Company Update Conference Call on Wednesday, Marc Mar 25 2016 
Atossa Genetics Announces the Opening of Its First Phase 2 Clinical Trial of Intraductal Fulvestrant Mar 02 2016 
Atossa Genetics Completes Sale of Its Wholly-Owned Subsidiary The National Reference Laboratory for Dec 17 2015 
Atossa Genetics Hires Janet Rose Rea, M.S.P.H. as VP Regulatory Affairs and Quality Oct 14 2015 
Atossa Genetics to Present at Upcoming Investor Conferences Oct 09 2015 
Atossa Genetics' Laboratory Receives ISO 15189:2012 Certification Sep 25 2015 

More From Other Websites
Atossa Genetics Receives Positive Interim Review From Independent Safety Committee in Phase 1... Apr 20 2017
Atossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study Apr 04 2017
Atossa Genetics Closes Public Offering Apr 03 2017
Seattle breast cancer company stock plummets as it seeks funding to continue operations Mar 29 2017
Atossa Genetics, Inc. Prices $4,000,000 Public Offering Mar 29 2017
Atossa Genetics Opens Enrollment in Study of Endoxifen Mar 23 2017
ATOS: Pure Player in the Breast Care Space Mar 17 2017
Atossa Genetics Provides Update on its Phase 2 Study of Fulvestrant Administered with its... Jan 09 2017
Atossa Genetics to Present at the 9th Annual Biotech Showcase Conference on January 9, 2017 Jan 05 2017
Atossa Genetics Appoints Jack Cuzick, PhD, FRS, FMedSci, FRCP (hon) as Scientific Advisor Dec 23 2016
Atossa Genetics Announces Reverse Stock Split Aug 25 2016
Atossa Genetics to Provide Company Update and Discuss Second Quarter Financial Results on Conference... Aug 10 2016
Atossa Genetics Settles Litigation With Besins Healthcare Aug 05 2016
SeeThruEquity Initiates Coverage on Atossa Genetics, Inc. with a Price Target of $1.15 Jun 30 2016
Atossa Genetics Initiates Additional Drug Development Program Jun 07 2016
Atossa Genetics to Present at 6th Annual LD Micro Invitational Conference on June 7th, 2016 May 31 2016
Atossa Genetics Announces $10 Million At-the-Market Common Stock Purchase Agreement With Aspire... May 27 2016
Atossa Genetics Announces First Quarter 2016 Financial Results and Provides Company Update May 05 2016
Atossa Genetics to Host First Quarter 2016 Financial Results and Company Update Conference Call on... May 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)